PAPZIMEOS: Breakthrough Treatment for Respiratory Papillomatosis

Precigen has announced that their drug, PAPZIMEOS, is showing promising long-term results for treating recurrent respiratory papillomatosis (RRP). Impressively, 83% of patients have maintained complete responses for at least 36 months, with some going beyond four years without needing more treatment. The FDA has granted the drug a seven-year market exclusivity, making it the only approved therapy for RRP. What does it mean for you? If you or someone you know is affected by RRP, this could be a game-changer, potentially reducing the need for frequent surgeries and improving quality of life with a long-lasting treatment option.